Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary aim of this french multicenter national study is to assess and compare time to quality of life score deterioration (targeted dimensions : global health, fatigue and emotional functionning of EORTC QLQC30 according to the first line chemotherapy associated with bevacizumab in metastatic colorectal patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| irinotecan based chemotherapy | patients having a 1st line doublet chemotherapy including irinotecan |
| |
| oxaliplatin based chemotherapy | patients having a 1st line doublet chemotherapy including oxaliplatin |
| |
| triplet chemotherapy | patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bevacizumab | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning) | The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| time to health related quality of life score deterioration (non targeted dimensions of EORTC QLQC30 and CR 29) | 1 year | |
| INT PATSAT32 | The EORTC IN-PATSAT32 is a 32-item satisfaction with care questionnaire to measure patients' appraisal of hospital doctors and nurses, as well as aspects of care organisation and services. It addresses technical competence, information provision, interpersonal skills, availability, waiting time, access, comfort and overall care perception |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
metastatic colorectal cancer
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marion Jacquin, Msc | Contact | 0033370632171 | fbonnetain@chu-besancon.fr | |
| Ikram El SaaD, Msc | Contact | 0033370632181 | iessaad@chu-besancon.fr |
| Name | Affiliation | Role |
|---|---|---|
| Franck Bonnetain, PhD | University Hospital of Besancon | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU Besançon | Recruiting | Besançon | Franche Comté | 25030 | France |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year |
| quality-adjusted life years (QALYs) using EQ5D | 1 year |
| Overall survival | 2 years |
| Progression Free Survival | 1 year |
| treatment preference | 1 year |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068258 | Bevacizumab |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided